Regeneron Pharmaceuticals Inc.

598.54-5.74-0.95%Vol 850.10K1Y Perf 97.56%
Jun 4th, 2020 16:00 DELAYED
BID597.43 ASK598.54
Open596.99 Previous Close604.28
Pre-Market601.00 After-Market598.54
 -3.28 -0.54%  - -%
Target Price
558.11 
Analyst Rating
Moderate Buy 1.95
Potential %
-6.75 
Finscreener Ranking
★★★★     55.60
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     58.90
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     75.74
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap65.85B 
Earnings Rating
Sell
Price Range Ratio 52W %
94.19 
Earnings Date
5th May 2020

Today's Price Range

592.79610.99

52W Range

271.37618.71

5 Year PE Ratio Range

12.70197.40

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-2.33%
1 Month
4.21%
3 Months
22.61%
6 Months
62.50%
1 Year
97.56%
3 Years
24.63%
5 Years
10.96%
10 Years
2 023.24%

TickerPriceChg.Chg.%
REGN598.54-5.7400-0.95
AAPL322.32-2.8000-0.86
GOOG1 412.18-24.2000-1.68
MSFT182.92-2.4400-1.32
XOM49.10-0.1400-0.28
WFC30.361.53005.31
JNJ146.73-1.9200-1.29
FB226.29-3.8700-1.68
GE7.740.38005.16
JPM106.442.17002.08
Financial StrengthValueIndustryS&P 500US Markets
3.40
4.20
0.06
0.06
90.20
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
90.10
31.00
33.60
34.30
28.56
RevenueValueIndustryS&P 500US Markets
7.98B
72.10
14.68
18.64
Earnings HistoryEstimateReportedSurprise %
Q01 20204.895.8720.04
Q04 20196.036.589.12
Q03 20195.135.8413.84
Q02 20194.605.2915.00
Q01 20195.243.75-28.44
Q04 20185.105.9216.08
Q03 20184.945.103.24
Q02 20184.484.704.91
Earnings Per EndEstimateRevision %Trend
6/2020 QR5.60-12.64Negative
9/2020 QR6.15-7.66Negative
12/2020 FY23.84-9.90Negative
12/2021 FY31.567.13Positive
Next Report Date-
Estimated EPS Next Report4.89
Estimates Count1
EPS Growth Next 5 Years %19.70
Volume Overview
Volume850.10K
Shares Outstanding110.02M
Trades Count24.20K
Dollar Volume544.93M
Avg. Volume1.38M
Avg. Weekly Volume2.40M
Avg. Monthly Volume2.00M
Avg. Quarterly Volume1.58M

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock closed at 598.54 per share at the end of the most recent trading day (a -0.95% change compared to the prior day closing price) with a volume of 851.81K shares and market capitalization of 65.85B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 7400 people. Regeneron Pharmaceuticals Inc. CEO is Leonard S. Schleifer.

The one-year performance of Regeneron Pharmaceuticals Inc. stock is 97.56%, while year-to-date (YTD) performance is 59.41%. REGN stock has a five-year performance of 10.96%. Its 52-week range is between 271.37 and 618.71, which gives REGN stock a 52-week price range ratio of 94.19%

Regeneron Pharmaceuticals Inc. currently has a PE ratio of 30.80, a price-to-book (PB) ratio of 5.68, a price-to-sale (PS) ratio of 8.31, a price to cashflow ratio of 31.50, a PEG ratio of 2.32, a ROA of 15.93%, a ROC of 20.04% and a ROE of 21.13%. The company’s profit margin is 28.56%, its EBITDA margin is 33.60%, and its revenue ttm is $7.98 Billion , which makes it $72.10 revenue per share.

Of the last four earnings reports from Regeneron Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $4.89 for the next earnings report. Regeneron Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Regeneron Pharmaceuticals Inc. is Moderate Buy (1.95), with a target price of $558.11, which is -6.75% compared to the current price. The earnings rating for Regeneron Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Regeneron Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Regeneron Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 19.41, ATR14 : 24.56, CCI20 : 122.28, Chaikin Money Flow : 0.33, MACD : 17.16, Money Flow Index : 58.08, ROC : 7.34, RSI : 57.91, STOCH (14,3) : 79.14, STOCH RSI : 0.60, UO : 65.61, Williams %R : -20.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Regeneron Pharmaceuticals Inc. in the last 12-months were: Andrew J Murphy (Sold 8 000 shares of value $2 727 279 ), Arthur Frederick Ryan (Option Excercise at a value of $18 729 668), Arthur Frederick Ryan (Sold 50 471 shares of value $27 791 038 ), Christopher R. Fenimore (Option Excercise at a value of $225 616), Christopher R. Fenimore (Sold 2 882 shares of value $1 218 761 ), Daniel P. Van Plew (Option Excercise at a value of $5 455 348), Daniel P. Van Plew (Sold 55 225 shares of value $29 489 318 ), George D. Yancopoulos (Option Excercise at a value of $17 982 559), George D. Yancopoulos (Sold 235 938 shares of value $105 059 775 ), George L. Sing (Option Excercise at a value of $616 800), George L. Sing (Sold 25 250 shares of value $11 078 750 ), Huda Y. Zoghbi (Option Excercise at a value of $2 005 846), Huda Y. Zoghbi (Sold 5 118 shares of value $2 899 461 ), Joseph J. Larosa (Option Excercise at a value of $2 660 033), Joseph J. Larosa (Sold 24 813 shares of value $13 458 373 ), Joseph L. Goldstein (Option Excercise at a value of $167 100), Joseph L. Goldstein (Sold 9 500 shares of value $4 217 362 ), Leonard S. Schleifer (Option Excercise at a value of $16 210 375), Leonard S. Schleifer (Sold 150 922 shares of value $85 908 038 ), Marc Tessier-Lavigne (Option Excercise at a value of $3 425 244), Marc Tessier-Lavigne (Sold 29 279 shares of value $14 171 206 ), Michael S. Brown (Option Excercise at a value of $4 908 274), Michael S. Brown (Sold 12 309 shares of value $4 921 128 ), Neil Stahl (Option Excercise at a value of $4 452 675), Neil Stahl (Sold 41 599 shares of value $18 229 506 ), P. Roy Vagelos (Option Excercise at a value of $5 736 051), P. Roy Vagelos (Sold 223 585 shares of value $111 990 855 ), Robert E. Landry (Option Excercise at a value of $9 953 550), Robert E. Landry (Sold 9 006 shares of value $4 743 561 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (52.38 %)
11 (50.00 %)
11 (55.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
10 (47.62 %)
11 (50.00 %)
9 (45.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.95
Moderate Buy
2.00
Moderate Buy
1.90

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

CEO: Leonard S. Schleifer

Teplephone: +1 914 847-7000

Address: 777 Old Saw Mill River Road, Tarrytown 10591-6707, NY, USA

Number of employees: 7 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

52%48%

Bearish Bullish

43%57%

News

Stocktwits